Brief: Celyad: Update On CYAD-01 Solid Tumor Clinical Program

Celyad Oncology SA

09/11/2018 17:52

Nov 9 (Reuters) - CELYAD SA  CYAD.BR :
    * STANDALONE CYAD-01 WITHOUT PRECONDITIONING LEADS TO
DISEASE
STABILIZATION IN THREE OUT OF 11 METASTATIC COLORECTAL CANCER
(MCRC) PATIENTS IN THINK PHASE 1 TRIAL
    * PRELIMINARY SAFETY DATA FROM THINK CYFLU COHORT,
EVALUATING
CYAD-01 WITH PRECONDITIONING, REMAINS ENCOURAGING WITH
IMPROVEMENT IN CYAD-01 KINETICS
    * OVERALL, FIVE OUT OF SEVEN (71%) PATIENTS ACHIEVED
MEANINGFUL
DECREASE IN BONE MARROW BLASTS
    * SHRINK PHASE 1 TRIAL UPDATE: INITIAL ACTIVITY RESULTS
ASSESSED
BY PATHOLOGICAL RESPONSE CRITERIA SHOWED ALL THREE PATIENTS
ACHIEVED AN OBJECTIVE CLINICAL RESPONSE
    * SHRINK PHASE 1 TRIAL UPDATE: CONCURRENT TREATMENT OF
CYAD-01
WITH FOLFOX CHEMOTHERAPY APPEARS TO BE WELL TOLERATED
    * SHRINK PHASE 1 TRIAL UPDATE: HE EXPANSION OF PERIPHERAL
CYAD-01
CELLS WITH A CONCURRENT ADMINISTRATION OF FOLFOX CHEMOTHERAPY IS
SIMILAR TO THE ONE OBSERVED WITH THE STANDALONE CYAD-01
    * SHRINK PHASE 1 TRIAL UPDATE: FULL DATA FROM THE SHRINK
PHASE 1
TRIAL ARE EXPECTED IN MID-2019
    * THINK CYFLU PHASE 1 COHORT UPDATE: TREATMENT WITH CYAD-01
FOLLOWING STANDARD PRECONDITIONING REGIMEN OF CYFLU WAS WELL
TOLERATED
    * THINK CYFLU PHASE 1 COHORT UPDATE: PRELIMINARY
TRANSLATIONAL
DATA SUGGEST AN IMPROVEMENT IN THE CELL EXPANSION OF CYAD-01
INDUCED BY THE CYFLU PRECONDITIONING.
    * THINK CYFLU PHASE 1 COHORT UPDATE: FULL DATA FROM THE
THINK
CYFLU PHASE 1 COHORT ARE EXPECTED IN MID-2019.

Source text: https://bit.ly/2DtbCYJ
Further company coverage:  CYAD.BR 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))